Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
GYRE
GYRE
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
GYRE News
Gyre Therapeutics Acquires Cullgen in $300 Million All-Stock Deal
Mar 02 2026
stocktwits
Altimmune Inc Receives FDA Breakthrough Therapy Designation for Pemvidutide, Shares Surge 23.6%
Jan 05 2026
Benzinga
Gyre Pharmaceuticals Reaches Pre-NDA Consensus with China's CDE for Hydronidone Approval
Jan 05 2026
Globenewswire
Gyre Pharmaceuticals Reaches Pre-NDA Consensus with China's CDE for Hydronidone Approval
Jan 05 2026
Yahoo Finance
GYRE THERAPEUTICS, INC. Reports Increase in Q3 Earnings
Nov 07 2025
NASDAQ.COM
Fresh Strong Sell Stocks for October 17th
Oct 17 2025
NASDAQ.COM
Gyre Therapeutics Emerges as a Notable Player in Liver Fibrosis Drug Development
Aug 26 2025
Benzinga
Actuate Therapeutics Analyst Starts Coverage Positively; Check Out Tuesday's Top 3 Initiations
Aug 26 2025
Benzinga
Gyre Therapeutics Appoints Dr. Dan Weng to Its Board of Directors
Aug 22 2025
Newsfilter
Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China
Jun 10 2025
Newsfilter
MAC Copper, ATS, Pony AI And Other Big Stocks Moving Higher On Tuesday
May 27 2025
Benzinga
Ross Stores, Deckers Outdoor, Xerox Holdings And Other Big Stocks Moving Lower In Friday's Pre-Market Session
May 23 2025
Benzinga
Gyre Therapeutics slumps 16%, prices $20M stock offering
May 23 2025
SeekingAlpha
Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock
May 23 2025
Newsfilter
Gyre : Phase 3 Trial Of Hydronidone In Chronic Hepatitis B Meets Main Goal; Prices $20 Mln Offering
May 23 2025
NASDAQ.COM
Gyre Therapeutics Announces Proposed Underwritten Public Offering of Common Stock
May 22 2025
Newsfilter
Show More News
